Microvesicles as risk markers for venous thrombosis.

Area of Science:

• Biochemistry
• Hematology
• Oncology

Background:

• Microvesicles (MVs) are cell-derived vesicles implicated in various physiological and pathological processes.
• MVs can possess procoagulant properties due to surface-bound tissue factor (TF) and negatively charged phospholipids like phosphatidylserine.
• Plasma MVs are being investigated as potential biomarkers for diseases, including venous thrombosis.

Purpose of the Study:

• To review the utility of plasma microvesicles as biomarkers for venous thrombosis.
• To evaluate the association between different types of MVs (phosphatidylserine-positive, platelet-derived, TF-positive) and venous thromboembolism.
• To explore the predictive potential of TF-positive MVs in cancer patients for venous thrombosis development and survival.

Main Methods:

• Literature review of studies investigating plasma microvesicles and venous thrombosis.
• Analysis of findings regarding phosphatidylserine-positive MVs, platelet MVs, and TF-positive MVs in relation to venous thromboembolism.
• Examination of studies focusing on TF-positive MVs in pancreatic cancer patients and their correlation with thrombosis and survival.

Main Results:

• Most studies found no clear link between venous thrombosis and phosphatidylserine-positive MVs or platelet MVs.
• Elevated levels of TF-positive MVs were observed in patients with venous thromboembolism.
• In pancreatic cancer patients, increased TF-positive MVs may predict venous thrombosis and poorer survival.

Conclusions:

• TF-positive microvesicles show potential as a biomarker for venous thrombosis, especially in cancer contexts.
• Current evidence suggests TF-positive MVs are more reliably associated with venous thromboembolism than other MV types.
• Further research is essential to validate TF-positive MVs as a robust biomarker for venous thrombosis in diverse patient populations and diseases.